Suppr超能文献

肿瘤血栓类型影响伴有门静脉肿瘤血栓的肝细胞癌的预后。

Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein.

作者信息

Shuqun Cheng, Mengchao Wu, Han Chen, Feng Shen, Jiahe Yang, Guanghui Ding, Wenming Cong, Peijun Wang, Yuxiang Zhao

机构信息

Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, PR China.

出版信息

Hepatogastroenterology. 2007 Mar;54(74):499-502.

Abstract

BACKGROUND/AIMS: To evaluate the benefits of the tumor thrombus types system on determining treatments and prognosis of hepatocellular carcinoma patients (HCC) with tumor thrombi in the portal vein.

METHODOLOGY

According to anatomic features of the portal vein in the liver and tumor thrombus of HCC developing modes, a uniform tumor thrombus types system (types I-IV) was first recommended. 84 HCC patients with portal vein tumor thrombi, which from January 2000 to January 2003 in the Eastern Hepatobiliary Surgery Hospital, were divided into I-IV groups according to types I-IV of the tumor thrombus system. The median survival periods and effectiveness of surgical resection or non-resection for I-IV groups were retrospectively observed.

RESULTS

The median survival periods for patients of group I (n=17), II (n=26), III (n=35) and group IV (n=6) were 10.1, 7.2, 5.7 and 3.0 months, respectively (p = 0.0001). From tumor thrombus type I to type III, the patients received surgical resection were better than that of non-resection (P = 0.0006). Among the patients receiving resection treatment, resection of tumor thrombus type I had the best effects, while for patients with tumor thrombus type IV, the results were not good. In case of non-resection treatments, the survival periods of patients with tumor thrombi type I, II and III were similar, which supposed that TACE may be of little effects on tumor thrombi.

CONCLUSIONS

Types of tumor thrombus system suggested may be helpful to determine the treatments and prognosis of HCC patients with tumor thrombi in the portal vein.

摘要

背景/目的:评估肿瘤血栓分型系统在确定门静脉有肿瘤血栓的肝细胞癌(HCC)患者治疗方案及预后方面的作用。

方法

根据肝脏门静脉的解剖特征及HCC肿瘤血栓的发展模式,首次推荐了统一的肿瘤血栓分型系统(I-IV型)。将2000年1月至2003年1月在东方肝胆外科医院收治的84例伴有门静脉肿瘤血栓的HCC患者,按照肿瘤血栓系统的I-IV型分为I-IV组。回顾性观察I-IV组手术切除或非手术切除的中位生存期及疗效。

结果

I组(n = 17)、II组(n = 26)、III组(n = 35)和IV组(n = 6)患者的中位生存期分别为10.1、7.2、5.7和3.0个月(p = 0.0001)。从肿瘤血栓I型到III型,接受手术切除患者的情况优于未接受手术切除者(P = 0.0006)。在接受切除治疗的患者中,肿瘤血栓I型切除效果最佳,而对于肿瘤血栓IV型患者,效果不佳。在非手术治疗情况下,肿瘤血栓I型、II型和III型患者的生存期相似,这表明经动脉化疗栓塞术(TACE)对肿瘤血栓可能效果甚微。

结论

所建议的肿瘤血栓分型系统可能有助于确定门静脉有肿瘤血栓的HCC患者的治疗方案及预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验